A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.

Inclusion Criteria: * Willing and able to give informed consent. * Male or female, aged 18 years or above. * Stable disease for at least three months prior to study entry, in the opinion of the investigator. * Diagnosed with MS whose spasticity was not wholly relieved with the therapy at the time of study entry. * Significant spasticity in at least two muscle groups defined as a score of two or more on the Ashworth Scale for each muscle group. * Stable dose of current anti-spasticity medication for at least 30 days prior to study entry. * Willing to maintain a stable dose of anti-spasticity medication and level of physiotherapy for the duration of the study. * Clinically acceptable laboratory results at Visit 2. * Willing, if female and of child bearing potential or male subjects with a partner of child bearing potential, to ensure that effective contraception was used during the study and for three months thereafter. * No cannabinoid use (cannabis, Marinol® or Nabilone) for at least seven days before Visit 1 and were willing to abstain from any use of cannabis during the study. * Able (in the investigators opinion) and willing to comply with all study requirements. * Willing for the Home Office to be notified of his or her participation in the study (applicable to the UK centres only). * Willing to allow his or her GP and consultant, if appropriate, to be notified of participation in the study. Exclusion Criteria: * History of schizophrenia, other psychotic illness, sever…